Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, . . . Kim A. Papp. (2024). Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy. Elsevier.
Chicago Style (17th ed.) CitationAndrew Blauvelt, et al. Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy. Elsevier, 2024.
MLA (9th ed.) CitationAndrew Blauvelt, et al. Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy. Elsevier, 2024.
Warning: These citations may not always be 100% accurate.